Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer"
DOI: 10.1186/s12943-018-0805-1
Abstract: The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory hematological, cytogenetic and molecular remissions. However, approximately 15–20% fail to… read more here.
Keywords: myeloid leukemia; non abl; chronic myeloid; leukemia ... See more keywords